ライフサイエンスコーパス: oral disease

1 ne use, select co-usage elevated the risk of oral disease.

2 identification of meaningful biomarkers for oral disease.

3 a role in the development of tobacco-related oral disease.

4 dults (aged 18-85 years) without systemic or oral disease.

5 nfluenced by host genotype and their role in oral disease.

6 xiety) are plausible risk factors for future oral disease.

7 ed metabolic pathways that may contribute to oral disease.

8 diamine fluoride as essential medicines for oral disease.

9 caries (tooth decay), a prevalent pediatric oral disease.

10 rly-childhood caries, a prevalent and costly oral disease.

11 regime shift"), which promotes dysbiosis and oral disease.

12 f bacteria in the progression of this common oral disease.

13 t likely to develop (any or severe forms of) oral disease.

14 ationship between obesity-associated T2D and oral disease.

15 cious feed-forward loop between systemic and oral disease.

16 potential target for preventing this common oral disease.

17 cer, chronic lung and vascular diseases, and oral disease.

18 -induced effector molecules in resistance to oral disease.

19 he pathogenesis of different biofilm-related oral diseases.

20 ploit arginine catabolism for the control of oral diseases.

21 their uncontrolled outgrowth can express as oral diseases.

22 ckness or health is a key to combating human oral diseases.

23 ll patients with HIV infection will contract oral diseases.

24 ely unexplored, especially in the context of oral diseases.

25 ing the dysbiotic transitions from health to oral diseases.

26 disease predisposition and/or progression in oral diseases.

27 ome and a potential increase in frequency of oral diseases.

28 and project the occurrence and prognosis of oral diseases.

29 spective of the high prevalence of untreated oral diseases.

30 nty-eight NCDs were strongly associated with oral diseases.

31 updated strategies to treat and prevent the oral diseases.

32 the prevention, monitoring, and diagnosis of oral diseases.

33 rvations apply equally to the study of other oral diseases.

34 erns about their role in the pathogenesis of oral diseases.

35 oved intervention strategies for MMP-related oral diseases.

36 ietal relevance of preventing and addressing oral diseases.

37 an oral bacterium implicated in a variety of oral diseases.

38 2) and from a control group (n = 27) without oral diseases.

39 w drugs are developed for pathways common to oral diseases.

40 l associations of DG with various autoimmune oral diseases.

41 eroxidase systems during the pathogenesis of oral diseases.

42 Chronic, untreated oral disease adversely affects one's systemic health, qu

43 the focal infection theory that posited that oral disease affects overall health and wellbeing.

44 Providers should expect higher levels of oral disease among patients with adverse mental health s

45 aim to highlight the urgent need to address oral diseases among other NCDs as a global health priori

46 alable interventions to tackle the burden of oral diseases among people with mental disorders.

47 The burden of oral diseases among this group is substantial given thei

48 er prevalence of chronic diseases, including oral diseases, among underrepresented minorities.

49 The link between oral disease and cardiovascular disease was established

50 gingivalis co-occur in metagenomic data from oral disease and healthy human cohorts.

51 a scientific model for the understanding of oral disease and its consequences.

52 whelming dominance of social determinants on oral disease and the difficulty of translating science i

53 Dental caries is the most common oral disease and the most common cause of resin restorat

54 lyses estimated genetic correlations between oral diseases and cardiovascular disease outcomes.

55 s oral health goals of reducing the level of oral diseases and minimizing their impact by 2020.

56 he oral health goal of reducing the level of oral diseases and minimizing their impact is to be achie

57 rimental role of sugars as a risk factor for oral diseases and other NCDs has also been well document

58 Combating the commercial determinants of oral diseases and other NCDs should be a major policy pr

59 Despite the evidence, oral diseases and sugars are not part of the current NCD

60 iewpoint, we advocate for the integration of oral diseases and sugars into the current approach towar

61 Oral diseases and sugars remain sidelined, disproportion

62 een the oral microbiota and the pathology of oral diseases and systemic diseases.

63 he association between different measures of oral diseases and the occurrence of PAD.

64 ioral and social implications of age-related oral diseases and tooth loss on several aspects of the q

65 s, and older people are the most affected by oral diseases, and have poor access to dental care.

66 trates a moderate role of genetic factors in oral diseases, and suggests potential gene-environment i

67 Oral diseases are a major global public health problem a

68 Oral diseases are among the most prevalent diseases glob

69 re compatible with the hypotheses that adult oral diseases are associated with the probability of exp

70 Clearly, oral diseases are highly prevalent in the globe, posing

71 Oral diseases are highly prevalent worldwide.

72 Both of these oral diseases are known to be caused not by the introduc

73 Although oral diseases are largely preventable, they persist with

74 Despite their prevalence and burdens, oral diseases are neglected in universal health coverage

75 e personal consequences of chronic untreated oral diseases are often severe and can include unremitti

76 Oral diseases are undoubtedly a global public health pro

77 and periodontal disease, the most widespread oral diseases, are commonly treated with various oral an

78 ex relationship between mental disorders and oral diseases, as well as inform the design of complex i

79 To investigate changes in the pattern of oral disease associated with highly active antiretrovira

80 used by Candida albicans, is the most common oral disease associated with human immunodeficiency viru

81 e clinical utility in treating LAP and other oral diseases associated with infection, inflammation, a

82 onal project that identified determinants of oral diseases at the community, family, and individual l

83 e is that now antiseptic products will treat oral disease better and oral health will improve.

84 nostic that enables rapid quantitation of an oral disease biomarker in human saliva by using a monoli

85 The BPT provides a measure of the oral disease burden, as both periodontal pathology and t

86 w approaches to defining and summarizing the oral disease burden.

87 Tobacco is a known cause of oral disease but the mechanism remains elusive.

88 disabilities have higher rates of asthma and oral disease, but similar rates of hypertension.

89 Instead, a wide range of oral diseases can mimic these lesions clinically.

90 surrogate endpoints, and new technologies in oral disease clinical trials.

91 sibility for every aspect of the impact that oral disease could have on the health and welfare of its

92 Apparently oral disease could, in fact, contribute to systemic dise

93 le summarizes causes of mental disorders and oral diseases, critically reviews current evidence on in

94 ntium associated with a higher prevalence of oral diseases (e.g., chronic periodontitis) in aged popu

95 ence supporting efficacy to prevent advanced oral disease endpoints, such as caries and periodontal d

96 health, we describe the scope of the global oral disease epidemic, its origins in terms of social an

97 In conclusion, the extent of oral disease for older individuals was significantly les

98 es among older adults have demonstrated that oral disease frequently leads to dysfunction, discomfort

99 robial community, while others are linked to oral diseases, from dental caries to gum disease.

100 The most prevalent and consequential oral diseases globally are dental caries (tooth decay),

101 Oral disease has implications beyond the mouth and can c

102 Childhood oral disease has significant medical and financial conse

103 inting out NCDs as putative risk factors for oral diseases have increased significantly but not with

104 e pediatricians on the epidemiology of child oral disease, highlight the importance of good oral heal

105 The costs of treating oral diseases impose large economic burdens to families

106 This pattern of oral disease in a referral clinic suggests that an incre

107 Periodontal disease is the most widespread oral disease in dogs which if left untreated results in

108 conclude that, in spite of the high rate of oral disease in persons with HIV, many do not use dental

109 ate and establish appropriate definitions of oral disease in pregnancy are warranted.

110 baseline, reflecting the natural history of oral disease in these animals, suggests individual varia

111 dies on multimorbidity have largely excluded oral diseases in multimorbidity prevalence estimates.

112 nce on interventions to reduce the burden of oral diseases in people with mental disorders, and sugge

113 Last we underscore select oral diseases in which C. albicans is a contributory mic

114 of intracellular PRRs in the pathogenesis of oral diseases including periodontitis and oral cavity ca

115 health, as well as prevent and treat common oral diseases, including appropriate rehabilitative serv

116 (CKD) were investigated to find out whether oral disease inflammatory burden or different etiology (

117 The risk of oral disease is higher among populations of Hispanic and

118 The findings show that experience of oral disease is more deleterious to subjective oral heal

119 he relationship between mental disorders and oral diseases is complex due to the shared social determ

120 Reporting the economic burden of oral diseases is important to evaluate the societal rele

121 Since death as a direct result of oral diseases is rare, DALY estimates were based on year

122 ders; however, their use in microbial-origin oral diseases is still preliminary.

123 Regular dental visitors had lower oral disease levels compared to episodic dental users.

124 ve disorders, a broad spectrum of collateral oral disease may be encountered.

125 However, recent studies indicate that this oral disease may have profound effects on systemic healt

126 the presence of oral dysbiosis that leads to oral diseases may directly and/or indirectly contribute

127 s with current measurement methodologies for oral diseases, measurable specific oral health goals sho

128 Kinase inhibitors have shown promising oral disease-modifying antirheumatic drug potential with

129 in rheumatoid arthritis (RA) patients taking oral disease-modifying antirheumatic drugs (DMARDs).

130 Complications can be reduced by the oral disease-modifying medication hydroxyurea, and in 20

131 No oral disease-modifying therapies are approved for beta-t

132 trial is the first phase 3 study comparing 2 oral disease-modifying therapies for relapsing multiple

133 Teriflunomide is an oral disease-modifying therapy approved for treatment of

134 rst study to report benefits of an available oral disease-modifying therapy in patients with early mu

135 Today, no oral disease-modifying treatments are available and chro

136 om the National Clinical Research Center for Oral Disease of China.

137 eople with NCDs have a greater prevalence of oral diseases particularly those with limited ability of

138 d in studies of craniofacial development and oral disease pathogenesis.

139 rs are at high risk for 2 bacterially driven oral diseases: peri-implant mucositis and peri-implantit

140 iggers an inflammatory loop in the prevalent oral disease periodontitis.

141 Vitamin D deficiency and oral diseases (periodontitis, caries, and tooth loss) ar

142 search's (NIDR) Division of Epidemiology and Oral Disease Prevention (DEODP) staff and consultants co

143 While certain craniofacial and oral diseases previously deemed too difficult to tackle

144 n important oral hygiene behavior to prevent oral disease progression in older adults.

145 ve risk of 8 for patients with ocular but no oral disease (pure ocular cicatricial pemphigoid, p < 0.

146 to provide a synthesis of sex differences in oral diseases, ranging from periodontal disease to orofa

147 Despite the high prevalence of oral diseases, related quality of life and values did no

148 Population studies of the prevalence of oral disease rely upon indices that summarize disease st

149 In many LMICs, oral diseases remain largely untreated because the treat

150 ion contributes to the pathogenesis of extra-oral diseases remains unclear.

151 Tissue loss due to oral diseases requires the healing and regeneration of t

152 r applications were used for illustration of oral disease risk profiles.

153 y and treatment response were assessed using Oral Disease Severity Score (ODSS), Oral Health Impact P

154 m, an opportunistic bacterial pathogen, from oral disease sites, such as those involved in refractory

155 biomarkers/diagnostic tools for systemic and oral disease states.

156 Novel 3D in vitro models of oral diseases such as cancer, Candida, and bacterial inv

157 ecognition among those in public health that oral diseases such as dental caries and periodontal dise

158 Accurate detection and early diagnosis of oral diseases such as dental caries and periodontitis, c

159 sition of these biofilms are associated with oral diseases such as dental caries or periodontitis.

160 emic disease, it is thought to contribute to oral disease, such as tooth loss, tissue changes in the

161 ved in two well-studied, microbiome-mediated oral diseases, such as butanoate production in periodont

162 vaccine, as well as vaccines to combat other oral diseases, such as dental caries and periodontal dis

163 urrently available drug delivery systems for oral diseases suffer from short retention time and poor

164 3.5 billion people have oral diseases, surpassing all other NCDs combined.

165 Chronic periodontitis (CP) is a common oral disease that confers substantial systemic inflammat

166 ressive periodontitis, a rapidly progressing oral disease that occurs in adolescents.

167 heterogeneity of the methods used to measure oral diseases, the treatment of confounding factors, the

168 By describing the extent and consequences of oral diseases, their social and commercial determinants,

169 as been reported to correlate with different oral diseases, there appears to be an absence of researc

170 ound at higher levels in individuals free of oral disease (vs.

171 The utility of mycotypes as biomarkers for oral diseases warrants further study.

172 Oral disease was associated with excess cardiovascular d

173 nce of the DQB1*0301 allele in patients with oral disease was not statistically significant (64%, 7/1

174 Moreover, when >/=3 oral diseases were cumulated in the model, the risk incr

175 AP8, and PLB1 expression was correlated with oral disease, whereas SAP1, SAP3, and SAP6-SAP8 expressi

176 nF(2) stabilization, to prevent a widespread oral disease with reduced fluoride exposure.

177 eta-analytic estimates on the association of oral diseases with NCDs.

178 ing a potential bidirectional association of oral diseases with systemic noncommunicable diseases (NC

179 ying mucosal immunology, initially exploring oral diseases, with special emphasis on the immunobiolog